Table 2.

Univariate analysis of clinicopathological parameters influencing recurrence-free survival (RFS) and overall survival (OS).

Variable	RFS			OS
	na	events	p valued	n	events	p value
Clinicopathological factors:
Tumour sizeb
pT1	46	10		48	8
pT2	83	39		86	30
pT3	11	5	< 0.001	12	3	0.001
pT4	24	16		27	18
Lymph node statusb
pN0	66	14		68	11
pN1-3	97	53	< 0.001	101	44	< 0.001
Histological grade
G1	18	4		19	5
G2	69	23		74	18
G3	78	43	< 0.001	80	37	0.003
Histological type
invasive ductal	138	63		142	50
invasive lobular	12	3		14	5
other	15	4	0.167	17	5	0.876
Estrogen receptor status
negative (IRSc 0–2)	46	24		46	19
positive (IRS 3–12)	93	32	0.065	98	28	0.076
Progesterone receptor status
negative (IRSc 0–2)	95	48		102	44
positive (IRS 3–12)	50	13	0.010	50	8	< 0.001
MIF protein expression
weak (IRSc 0–4)	51	26		57	27
strong (IRS 5–12)	114	44	0.033	117	32	0.002
EGFR status
negative (IRSc 0)	59	21		65	23
positive (IRS 1–3)	91	44	0.146	93	35	0.867

^a Only female patients with primary, unilateral, invasive breast cancer were included. ^b According to the TNM classification of Sobin and Wittekind [38]. ^c IRS = immunoreactive score according to Remmele and Stegner [35]. ^d Fisher's exact test. Significant p values are marked in bold face.